Raptor Pharmaceutical Corp Form 8-K					
January 09, 2013 UNITED STATES					
CITIED STATES					
SECURITIES AND EXCHANGE COMMISSION					
Washington, D.C. 20549					
FORM 8-K					
CURRENT REPORT					
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934					
Date of Report (Date of earliest event reported): January 9, 2013					
RAPTOR PHARMACEUTICAL CORP.					
(Exect name of registrent as analified in its abortor)					
(Exact name of registrant as specified in its charter)					
Delaware 000-25571 86-0883978					
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)					
9 Commercial Blvd., Suite 200, Novato, California 94949					
(Address of principal executive offices and Zip Code)					
Registrant's telephone number, including area code: (415) 382-8111					
(Former name or former address, if changed since last report)					
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of					
the registrant under any of the following provisions (see General Instruction A.2. below):					
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)					
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)					
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))					

Item 2.02 Results of Operations and Financial Condition.

On January 9, 2013, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release reporting its financial results for the Company's first quarter ended November 30, 2012. A copy of the press release is being furnished as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Item 2.02 of this Current Report on Form 8-K, including the information incorporated by reference in the exhibit hereto, shall not be deemed "filed" for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) E	Exhibits.

		Furnished	
Exhibi	t	Here	Incorporated by Reference
No.	Exhibit Description	with	Form File No. Exhibit Filing Date By
99.1	Press release issued by the Company dated as of January 9, 2013	X	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: January 9, 2013 By:

3y: /s/ Christopher M. Starr, Ph.D.

Name: Christopher M. Starr, Ph.D.

Title: Chief Executive Officer and Director

Exhibit Index

Exhibit

No. Exhibit Description

Press release issued by the Company dated as of January 9, 2013

Press release issued by the Company dated as of January 9, 2013